Diagnostic Solutions Account Executive
About the job
- A bachelor's degree in life sciences, biological areas, business, or a related field is required.
- At least three years of documented sales success in a broad range of laboratory products, including at least one year of clinical laboratory and/or hospital sales experience.
- A combination of clinical market sales, financial selling, or technical selling experience is required.
- Experience attaining or exceeding overall sales plan profitability and other assigned goals and objectives is required.
- Knowledge of the selling process and the components needed to build and maintain customer loyalty is required.
- Preparation, presentation, and closing skills, including direct sales, distribution-channel sales, and/or a team-selling approach, are required.
- Strong organizational skills, territory management, account assessment, and relationship development are required.
- Analytical skills and a financial orientation applicable to contract proposals, profitability, budget, and expense management are required.
- Ability to develop markets for new technology and new medical practices is required.
- Excellent communication skills and interpersonal interaction are required.
- Computer proficiency, including working knowledge of Microsoft Office applications, Salesforce.com, Power BI, and connectivity devices, is required.
- A valid state-issued driver's license must be maintained, and the candidate must meet BD's auto safety standards.
- Develop and implement a territory and strategic-account sales plan involving multiple stakeholders and buyers to grow assigned products, including developing an account plan specific to each hospital's economic and strategic business drivers.
- Deploy clinically relevant product features, benefits, and economic justification using existing sales tools and creating tools for customer situations to define product value; coordinate decision-makers and influencers through the buying process to reach contractual purchase agreements.
- Maintain and grow the base revenue stream and ensure customer satisfaction through consistent, ongoing customer contact.
- Work with BD customer-facing associates, including Instrument Specialists, Clinical Specialists, Lab Automation Specialists, National Accounts, Strategic Customer Group Leaders, Service Engineers, and Applications Specialists, as well as distribution partners, to support customer growth and long-term retention.
- Attain or exceed the overall sales plan and provide customer support for the Diagnostic Solutions product portfolio, including Manual Microbiology, Blood Culture, TB, ID/AST, and Molecular Diagnostics.
- Manage the sales process with clinical laboratories, infectious disease clinicians, pharmacy, value analysis, and hospital administration, including laboratory committees, purchasing, supply chain management, IT, and senior hospital administration, within the assigned territory.
- Develop, document, and drive the customer buying process through full use of a territory and strategic-account sales plan involving multiple stakeholders and buyers.
- Call on prospective customers, create demand, communicate medical, clinical, and patient-outcome benefits, deliver product information and demonstrations, and coordinate new-customer acquisition strategies with the BD Diagnostic Solutions team.
- Demonstrate the soft and hard costs associated with the product portfolio and persuade multiple decision-makers and influencers to execute a successful product conversion within the institution.
- Develop account strategy and close accounts within the assigned geographic territory using a coordinated team-selling model involving internal specialists, national and strategic customer groups, service and applications specialists, distribution partners, and marketing.
- Communicate and coordinate customer needs, including inventory and supply-chain updates, contract changes, and competitive intelligence, to distributors to ensure account needs are met and opportunities are fully pursued.
- Prioritize and initiate direct sales calls with distributors to protect existing sales and identify additional revenue opportunities.
- Maintain effective customer resource management for accounts, including sales forecasts and sales activity, and close business as required by management.
- Provide ongoing post-sales support and communicate with the Service organization to coordinate successful installation and transition to long-term customer satisfaction.
- Perform assigned administrative duties, including monitoring expenses against budget, timely administrative and call reporting, funnel and competitive-data entry, managing new contracts and renewals, maintaining company assets, and adhering to OSHA requirements and universal laboratory precautions.
- Adhere to BD's values, Code of Conduct, and AdvaMed rules.
- A degree in Medical Technology (MT ASCP) or Microbiology is preferred.
About the company
BD (Becton, Dickinson and Company) is a global medical technology company that designs, manufactures, and sells medical devices, laboratory equipment, and related services for hospitals, labs, clinicians, and biopharma partners. It operates in four segments: Medical Essentials (medication delivery and specimen management devices), Connected Care (medication management and advanced patient monitoring systems), BioPharma Systems (drug delivery systems for pharmaceutical partners), and Interventional (surgical, endovascular, urological, and critical care products). In addition to devices, BD offers connected software, analytics, clinical education, customer portals, and service programs to support its products. The company’s goal is to help healthcare providers improve patient outcomes by enabling safer and more efficient delivery of care through integrated devices, data, and services across the health ecosystem.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 fiscal 2026 revenue rose 5.2% to $4.7 billion, and guidance rose.
- Fairview adopted BD Vmax 160 on September 14, validating pharmacy automation demand.
- Arthur Hu joins September 30, 2026 to accelerate AI and enterprise modernization.
What critics are saying
- BD still faces about 7,090 hernia claims, plus Georgia EtO litigation.
- June 30, 2026 restructuring included $450 million impairments, signaling portfolio damage.
- Repeated liability and sterilization verdicts could force another breakup or capital raise.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off leaves a pure-play MedTech platform.
- Its Pyxis, Incada, and Vmax 160 stack links dispensing, connected care, and robotics.
- Sixty-thousand employees and global hospital reach give BD unmatched distribution scale.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
10%1 year growth
10%2 year growth
10%BD celebrates 65 years of manufacturing, innovation and community partnership in Canaan. Generations of Connecticut employees have helped ensure the reliable supply of the BD(R) Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn., Oct. 6, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn., the birthplace of the world's first fully sterile, single-use disposable plastic syringe and the largest syringe manufacturing operation in the United States. The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. The invention of the BD(R) Syringe helped enable the shift away from reusable glass syringes, reducing the risk of patient-to-patient disease transmission. Today, more than 500 employees work at the 385,000-square-foot facility, producing more than 2 billion syringes each year, supporting care from routine vaccinations to critical procedures. Over six decades, the Canaan team has supported major public health efforts, including smallpox eradication, H1N1 vaccination programs and the COVID-19 response. "The BD(R) Syringe was invented here in Canaan as a breakthrough in patient safety and has become an essential part of care around the world, touching 80 patients every second," said Eric Borin, worldwide president, Medication Delivery Solutions at BD. "For 65 years, generations of employees have continued to improve how we manufacture while delivering the quality and precision clinicians count on. This milestone is a testament to their dedication and the difference their work makes for patients every day." BD has invested more than $34 million in the Canaan site over the past five years to expand production capacity, modernize operations and support future growth. This includes three new syringe manufacturing lines and equipment upgrades that strengthen supply assurance. These investments reflect BD's commitment to U.S. manufacturing and to helping healthcare systems maintain reliable access to high-quality medical technologies. "Connecticut has a proud history of turning innovation into products that improve people's lives, and BD's Canaan facility is a powerful example," said Governor Ned Lamont. "For 65 years, this site has supported good jobs, strengthened our manufacturing economy and produced medical devices used in patient care around the world. BD's continued investment in Canaan demonstrates the strength of Connecticut's workforce and the important role our state plays in manufacturing essential healthcare products." A Connecticut legacy with global reach BD leaders, elected officials, employees and community partners gathered at the Canaan facility to celebrate its 65-year history and contributions to healthcare, manufacturing and the regional economy. That legacy is reflected in the generations of employees who have built careers at the site. More than 50 have at least 25 years of service, including 10 who have been with BD for 40 years or more. "BD has been an important part of northwestern Connecticut for 65 years, providing local jobs while manufacturing a product that supports patient care around the world," said State Representative Maria Horn and State Senator Stephen Harding in a joint statement. "The Canaan facility shows how advanced manufacturing can create meaningful opportunities in our communities while making a difference far beyond our state. We congratulate the employees who have made this milestone possible and welcome BD's continued investment in the region." As part of the celebration, BD will announce a $10,000 grant to the Community Health & Wellness Center, a Federally Qualified Health Center that provides accessible, high-quality healthcare to residents of northwestern Connecticut. The grant brings BD's support since 2024 to $90,000 helping fund nutrition programs, emergency assistance and transportation for patients in need. The partnership reflects BD's longstanding commitment to strengthening the communities where employees live and work. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with Becton, Dickinson and Company on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company)
RBC Capital remains a Hold on Becton Dickinson (BDX). Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Hold rating on Becton Dickinson on October 1 and set a price target of $190.00. The company's shares closed yesterday at $178.07. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $193.30. Based on Becton Dickinson's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.98 billion and a net profit of $377 million. In comparison, last year the company earned a revenue of $5.51 billion and had a net profit of $574 million Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year. Most recently, in August 2026, Thomas Polen, the COB, CEO & Pres of BDX sold 4,152.00 shares for a total of $768,120.00. Read More on BDX:
Compensation in a Tennessee Bard PowerPort Lawsuit. Table of contents. Introduction to the Bard PowerPort Lawsuit. Compensation in a Tennessee Bard PowerPort Lawsuit: Types of compensation that may be available to plaintiffs who are meet the criteria for a PowerPort Lawsuit include both economical and non economical damages. * Tennessee Bard PowerPort Lawsuit: Asserts allegations that Bard's implantable port systems were defectively designed and manufactured, leading to serious injuries in patients who relied on them for long-term vascular access. * Link to Fractures and Blood Clots: These devices, widely used for chemotherapy, long-term IV treatments, and other infusion therapies, have been linked to catheter fractures, infections, blood clots, migration, and vessel damage. * Litigation Landscape: Thousands of injured patients across the country have filed lawsuits claiming that Bard Access Systems, Inc. and its parent company, Becton, Dickinson and Company, failed to properly warn healthcare providers and patients about these risks. * Exposure to Life-Threatening Compications: Plaintiffs allege that flaws in the catheter's material and construction allowed the device to degrade inside the body, exposing them to life-threatening complications and emergency surgeries. * Multidistrict Litigation: All federal Bard PowerPort catheter lawsuits have been consolidated in Multidistrict Litigation (MDL No. 3081) before the United States District Court for the District of Arizona. * Coordinated Pretrial Proceedings: This consolidation allows a single district court to coordinate pretrial proceedings, manage discovery, and set the stage for bellwether trials. * Compensation in Bard PowerPort Lawsuit: Through this litigation, plaintiffs are pursuing financial compensation for their medical expenses, pain and suffering, lost wages, and other damages resulting from defective Bard PowerPort catheter devices. If you or a loved one, sufferd injuries or worse as a result of a defective Bard PowerPort Device, call Tennessee Bard PowerPort Lawsuit Lawyer Timothy L. Miles today. You may be eligible for a PowerPort Lawsuit and potentially be entited to substantial compensation in Bard PowerPort Lawsuit. (855) 846-6529 or [email protected]. The Defective Bard Powerport Device. The Bard PowerPort is an implantable port catheter system used to deliver chemotherapy, fluids, and medications directly into a patient's bloodstream. Lawsuits allege that the catheter's polyurethane material is prone to degrading, cracking, and fracturing. * Catheter Fracture and Fragmentation: Shards of the catheter can chip off and travel through the vascular system. These plastic fragments can puncture blood vessels, the lungs, or the heart. * Life-Threatening Risks: The Defective Bard Powerport Device can cause cardiac punctures, cardiac arrhythmia, pulmonary embolisms (blood clots in the lungs), and severe internal bleeding. * Emergency Surgeries: If a Defective Bard Powerport Device causes port fractures or migrates, patients frequently requireemergency surgical extraction to remove the shards from their blood vessels or organs before fatal damage occurs. Bard PowerPort Lawsuit updates. Bard PowerPort litigation updates (sept. 2026). * Court: U.S. District Court, District of Arizona (Judge David G. Campbell) * Litigatin Process: Currently in the discovery process, including document production, depositions, and testing of explanted devices * Core Allegations: Design defects, failure to warn, and negligent manufacturing * Injuries Reported: Catheter fracture, device migration, blood clots, and severe infections leading to hospitalization or sepsis * Next Phase: Bellwether trials scheduled to evaluate representative cases and guide potential settlements The discovery process has focused heavily on engineering analyses, company testing records, and physician testimony about complications observed in clinical practice. Bellwether cases have been selected to move toward trial, where juries will assess whether Bard's design and warnings were adequate under federal product liability law. While verdicts in bellwether trials apply only to the individual plaintiffs involved, they play an important role in shaping the overall litigation. Jury responses to evidence of design defects and corporate negligence will influence both sides' settlement strategies and may drive the framework for financial compensation across the MDL. Who is eligible for a Bard PowerPort Lawsuit. You may qualify for a PowerPort Lawsuit, if you had a defective Bard PowerPort catheter devices, implanted and developed any of the following complications: * Perforations of tissues, vessels and organs * Infections (sepsis or septic shock) * Deep Vein Thrombosis (DVT) * Hemorrhaging or Bleeding Injuries * Fluid buildup on the heart * Irregular Heartbeat * Severe and persistent pain * Chemotherapy leaking into the body * Wrongful death * Other injuries caused by fractured PowerPort catheter Reports of Defective Bard Powerport Catheter Devices and patient. * Defective Bard Powerport Catheter Devices: Thousands of patients have reported complications involving a catheter failure, migration, and infection after receiving one of the Defective Bard Powerport Catheter Devices, * Polyurethane Catheter: In many cases, the polyurethane catheter - often made with a polymer blend called Chronoflex AL - has fractured or degraded over time. * Seveve Internal Injuries: Fragments of the defective Bard Powerport device,may travel through the blood vessels, leading to vascular damage, embolisms, and other internal injuries. * Emergency Medical Procedures: These failures have triggered emergency medical procedures and even permanent harm for affected users. * Structural Integrithy of Weakened Cathete: Experts argue that the material, which contains high concentrations of barium sulfate to improve imaging visibility, may weaken the structural integrity of the catheter over time. Bard PowerPort MDL continues to grow, with more than 3,000 pending Bard PowerPort Lawsuits filed. * The MDL is overseen by Judge Campbell in the District of Arizona, where the court continues to manage the case through recurring status conference proceedings and structured pretrial scheduling. * New Bard PowerPort Lawsuits are currently being filed by lawyers across the country. * If you were injured or suffered other Bard PowerPort complications, you may be qualify for a PowerPort Lawsuit and potentially be entitled to substantial compensation in Bard PowerPort Lawsuit. If you or a loved one, sufferd injuries or worse as a result of a defective Bard PowerPort Device, call Bard PowerPort Lawsuit Lawyer Timothy L. Miles today. You may be eligible for a PowerPort Lawsuit and potentially be entited to substantial compensation in Bard PowerPort Lawsuit. (855) 846-6529 or [email protected].
Parsippany Engineer Dr. Trivikrama Reddy recognized with inaugural BD Community Excellence Award for global community impact. Sep 22, 2026 PARSIPPANY - Dr. Trivikrama Reddy, a Parsippany resident, Senior Staff Engineer at Becton, Dickinson and Company (BD), and Adjunct Professor at New Jersey Institute of Technology (NJIT), has been selected as an inaugural recipient of the BD Community Excellence Award, a global honor recognizing employees who have demonstrated exceptional commitment to improving communities through volunteerism, education, healthcare access, and sustainable development. The award celebrates BD associates who make a meaningful impact beyond their professional responsibilities by improving the lives of people in the communities where they live and work. According to BD, this year's recipients collectively strengthened healthcare access, expanded STEM education opportunities, supported vulnerable populations, and improved quality of life for people around the world. The award includes a $10,000 charitable grant awarded to a nonprofit organization selected by each recipient. Dr. Reddy was recognized for more than fifteen years of dedicated volunteer service supporting blood drives, health initiatives, STEM education programs, and community development projects. His most notable contribution was leading efforts to provide a sustainable and safe drinking-water solution to the tribal village of Rangasai in India, helping improve public health and reduce dependence on unsafe water sources. "Community service has always been an important part of my life," said Dr. Reddy. "I strongly believe that education, healthcare access, and clean water are fundamental necessities that can transform lives and create opportunities for future generations. I am honored to receive this recognition and grateful to everyone who supported these initiatives." Dr. Reddy's commitment to serving others extends across both his professional and academic careers. With more than 20 years of experience in medical device innovation and product development, he has contributed to technologies that improve patient outcomes worldwide. He currently serves as a Senior Staff Engineer at BD and is also an Adjunct Professor in the Mechanical Engineering Department at NJIT, where he has taught and mentored engineering students for the past eight years. In addition to his professional achievements, Dr. Reddy has actively promoted STEM education and community engagement through mentoring students, supporting educational programs, and encouraging young people to pursue careers in science, technology, engineering, and mathematics. "Dr. Reddy exemplifies the spirit of service and innovation," said Tom Polen, Chairman and Chief Executive Officer of BD. In recognizing this year's honorees, BD noted that recipients were selected for their leadership, dedication, and commitment to creating positive change in their communities. The company highlighted Dr. Reddy's efforts in improving community health, increasing access to safe water, and advancing STEM education as examples of meaningful and lasting impact. Beyond his engineering and educational contributions, Dr. Reddy has remained deeply involved in community service initiatives that create opportunities for underserved populations. His work reflects a belief that sustainable solutions and educational empowerment can have a lasting effect on individuals, families, and entire communities. The BD Community Excellence Award recognizes employees whose actions reflect the company's purpose of advancing health and improving lives. For Dr. Reddy, the recognition represents not only a personal achievement but also an affirmation of the collective efforts of volunteers, educators, healthcare professionals, and community leaders working together to make a difference. As he continues his professional, academic, and community service endeavors, Dr. Reddy hopes to inspire others to use their skills and expertise to address real-world challenges and create meaningful change in their communities.
Combination product industry news & guidance. Sharing device-related information and wisdom that will help you succeed. Adam Kalbermatten on why combination products CAN'T be on the critical path. In this episode, Parth Kothari and Jonathan Amaya-Hodges sit down with Adam Kalbermatten, Chief Executive Officer at Koru Medical Systems, whose thirty-year career has spanned engineering programs at Becton Dickinson, global marketing leadership at Terumo, and building and scaling ZebraSci as CEO through its acquisition by BD. Now leading the commercial organization at Koru, Adam is focused on large-volume subcutaneous infusion and expanding the label for IG patients in the SCIG market. The conversation covers what actually reduces risk in combination product development, why pharma partners often underestimate the complexity they're introducing, and why the most important thing a device supplier can be is a partner rather than a vendor. Adam is direct about what keeps him up at night, what it takes to build a cross-functional team that actually works, and why the biggest mistake development programs make is ending up on the critical path in the first place. Key takeaways: * Following proven regulatory pathways beats developing custom specifications, almost every time * How to surface risk cross-functionally before it becomes a program-level problem * What the supplier-partner distinction means in practice - and where pharma companies get it wrong * Why combination products that land on the critical path rarely escape it Connect with Adam Kalbermatten on LinkedIn